Skip to main content

4 Result(s)

within English Remove this filter Surgical Oncology Remove this filter Kazuo Nishimura Remove this filter

and
Your search also matched 11 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy

Include preview-only content

  1. Article

    Open Access

    Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma

    Cabozantinib was established as the standard of care for the treatment of patients with renal cell carcinoma (RCC) whose disease had progressed after vascular endothelial growth factor receptor tyrosine kinase...

    Noboru Nakaigawa, Yoshihiko Tomita… in International Journal of Clinical Oncology (2023)

    Download PDF (700 KB) View Article

  2. Article

    Open Access

    Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan

    Akira Yokomizo, Junji Yonese, Shin Egawa… in International Journal of Clinical Oncology (2022)

    Download PDF (309 KB) View Article

  3. Article

    Open Access

    Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan

    The purpose of the study is to evaluate real-world effectiveness and safety of enzalutamide in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) in Japan.

    Akira Yokomizo, Junji Yonese, Shin Egawa… in International Journal of Clinical Oncology (2022)

    Download PDF (800 KB) View Article

  4. Article

    Open Access

    Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

    The open-label, randomized, active-controlled KEYNOTE-045 study (NCT02256436) showed that second-line pembrolizumab significantly improved overall survival (OS) of patients with advanced/metastatic urothelial ...

    Hiroyuki Nishiyama, Yoshiaki Yamamoto… in International Journal of Clinical Oncology (2020)

    Download PDF (692 KB) View Article